DNAおよびRNA合成の調査レビュー：2024年

世界のDNAシーケンシングの市場規模は、2024年の148億米ドルから、予測期間中はCAGR 18.6%で推移し、2029年末には348億米ドルに達すると予測されています。

世界の次世代シーケンシングの臨床応用の市場規模は、2023年の219億米ドルから、予測期間中はCAGR 19.3%で推移し、2028年には529億米ドルに達すると予測されています。

世界のRNAシーケンシングの市場規模は、2024年の43億米ドルから、予測期間中はCAGR 19.1％で推移し、2029年末には103億米ドルに達すると予測されています。

DNAおよびRNA合成は、デオキシリボース核酸 (DNA) とリボ核酸 (RNA) を人工的に製造します。DNAおよびRNAを構築する合成技術の開発により、バイオロジーを理解し、エンジニアリングする能力が向上しました。オリゴヌクレオチド、遺伝子、DNAおよびRNA断片など、さまざまなタイプの合成DNAが利用可能であり、顧客のニーズに合わせて利用することができます。合成DNAやRNAは、新薬やワクチンの開発、遺伝性疾患の遺伝子治療、病原体や病気を検出するためのPCRアッセイや核酸ベースのセンサーなどの分子診断ツールの開発に使用されています。

DNAおよびRNAの合成技術は、合成生物学、分子遺伝学、生物工学などの科学分野で不可欠であり、様々な研究、診断、治療用途のカスタムDNAおよびRNA配列を作り出します。ゲノム研究の急速な拡大、治療用DNAおよびRNA用途の進歩、個別化医療のニーズの高まりが、DNAおよびRNA合成市場の大幅な成長を促しています。CRISPR、遺伝子治療、合成生物学の革新は、DNAおよびRNA合成の需要が急上昇していることを示しており、標的治療と革新的な遺伝子研究ソリューションの開発における極めて重要なツールとして位置づけられています。

当調査レビューは、BCC Researchが2024年に発行した遺伝子編集治療薬、DNAシーケンシング、次世代シーケンシング、RNAシーケンシングRNAi技術ウイルスベクターとプラスミドDNAに関するレポートのハイライトと抜粋を含み、それぞれの市場概要、市場影響因子および市場機会の分析、法規制環境、新興技術および技術開発の動向、市場規模の推移・予測、各種区分・地域別の詳細分析などをまとめています。

目次

第1章 序文

第2章 遺伝子編集治療薬市場 (BIO259A)

• 調査範囲
• 市場の展望
• 市場サマリー
• 遺伝子編集治療薬の市場概要
• ゲノム編集ツールの種類
• メガヌクレアーゼ
• ジンクフィンガーヌクレアーゼ
• 転写活性化因子様エフェクターヌクレアーゼ
• CRISPR /CRISPR関連タンパク質
• 遺伝子編集治療薬
• 市場力学
• 市場推進因子
• 市場の課題
• 遺伝子編集治療の新たな技術と機会
• ベース編集
• プライム編集
• Cas-CloverとCas-FOKl
• CRISPR干渉とCRISPR活性化
• RNA編集
• ゲノム編集におけるAI
• 遺伝子編集治療薬の市場分析
• 概要
• Casgevy
• 遺伝子編集治療薬市場：地域別
• 北米
• 欧州
• 新興市場
• 遺伝子編集治療市場におけるESGパフォーマンス
• 遺伝子編集企業におけるESGの実践
• BCCによる総論

第3章 世界のDNAシーケンシング：研究・応用・臨床市場 (BIO045J)

• 調査範囲
• 市場の展望
• 市場サマリー
• 市場概要
• DNAの重要性
• 遺伝的変異と分析
• NGS
• TGS (ロングリードシーケンシング)
• 研究と応用
• R&D用途
• 応用分野
• D2C
• バイオ医薬品
• 農業
• 法医学
• マイクロバイオーム
• 合成生物学
• 市場力学
• 市場推進因子
• 市場抑制因子
• 新興技術
• ロングリードシーケンシング技術
• SMRTシーケンシング
• ナノポアシーケンシング
• 空間ゲノミクスとトランスクリプトミクス
• 単一細胞DNAシークエンシング
• 超低入力シーケンシング
• CRISPR-Cas9とゲノム編集とシーケンシング技術の統合
• DNAシーケンシングにおけるAIと機械学習
• 市場内訳：技術別
• 概要
• NGS
• TGS
• サンガーシーケンシング
• パイロシーケンシング
• 市場内訳：地域別
• 北米
• 欧州
• アジア太平洋
• その他の地域
• DNAシークエンシング業界におけるESGパフォーマンス
• 環境パフォーマンス
• 社会的パフォーマンス
• ガバナンスパフォーマンス
• DNAシーケンシング業界におけるESGリスク評価
• BCCによる総論

第4章 次世代シーケンシング：新たな臨床用途と世界市場 (BIO126E)

• 調査範囲
• 市場の展望
• 市場サマリー
• 市場概要
• 液体および組織生検
• 臨床NGSの成長要因
• 主な動向
• 市場力学
• 市場推進因子
• 市場抑制因子
• 次世代シーケンシングの新たな技術
• 研究開発の取り組みとプログラム
• 1+ Million Genomes
• Access to Treatment and Testing (ACTT)
• Access to Comprehensive Genomic Profiling Coalition (ACGP)
• Africa Pathogen Genomics Initiative
• Blood Profiling Atlas
• Cancer-ID
• Cancer Moon Shots Program
• China Precision Medicine Initiative
• ClinGen
• CTC Trap Consortium
• diaRNAgnosis Project
• Early Cancer Detection Consortium
• EpiFemCare
• France Genomic Medicine Plan
• Friends of Cancer Research Project
• Genomic Medicine Sweden
• HCA-Organoid
• Human Cell Atlas
• Human Immunomics Initiative
• Immunomonitor Consortium
• Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
• Intervene
• Liquid Biopsies and Imaging for Improved Cancer Care
• Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
• Liver Cancer Early Screening Comprehensive Prevention and Control Project
• Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
• Million Veteran Program
• Medical Genome Initiative
• MedSeq
• 市場内訳：疾患カテゴリー別
• 概要
• 市場内訳：地域別
• 北米
• 欧州
• アジア太平洋
• 次世代シーケンシング業界におけるESGパフォーマンス
• ケーススタディ
• BCCによる見解

第5章 RNAシーケンシング：各種技術と世界市場 (BIO147B)

• 調査範囲
• 市場の展望
• 市場サマリー
• 市場概要
• 技術背景
• トランスクリプトミクス技術
• トランスクリプトミクスのためのRNAシーケンシング
• RNA-Seq実験ワークフロー
• RNAシーケンシングの規制状況
• 成長戦略の提案
• 市場力学
• 市場促進要因
• 市場抑制要因
• 市場機会
• RNAシーケンシング市場の新興技術と発展
• 単一細胞RNAシーケンシング
• その他の新興単一細胞技術
• 市場内訳：RNAシーケンシング製品
• 機器
• ツールと試薬
• ソフトウェアとサービス
• 市場内訳：地域別
• 概要
• 北米
• 欧州
• アジア太平洋
• その他の地域
• RNAシーケンシング市場における持続可能性：ESGの観点
• RNAシーケンシング業界におけるESG実践
• 環境パフォーマンス
• 社会的パフォーマンス
• ガバナンスパフォーマンス
• BCCによる総論

第6章 RNAi技術と世界市場 (BIO127C)

• 調査範囲
• 市場の展望
• 市場サマリー
• 市場概要
• RNA干渉の概要
• RNA干渉：作用機序
• 開始段階
• エフェクターフェーズ
• 低分子干渉RNA (siRNA)
• マイクロRNA (miRNA)
• 小型ヘアピンRNA (shRNA)
• 市場力学
• 市場促進要因
• 市場課題
• RNAi技術の新たな技術と機会
• 治療
• 診断
• 非侵襲的ヘルスモニタリングのための循環miRNA診断
• 農業
• 技術別市場
• 治療薬
• 診断
• 試薬とツール
• 農業
• 地域別市場
• 概要
• 北米
• 欧州
• 新興市場
• RNAi技術業界における持続可能性：ESGの観点
• 環境への取り組み
• 社会貢献活動
• ガバナンスの取り組み
• ケーススタディ
• BCCによる総論

第7章 ウイルスベクターとプラスミドDNA：各種技術と世界市場 (BIO192B)

• 調査範囲
• 市場の展望
• 市場サマリー
• 市場概要
• 細胞および遺伝子治療
• 市場力学
• 市場推進因子
• 市場の課題
• 新たな技術と機会
• ウイルスベクター生産におけるAI
• ドギーボーンDNA
• FRAGment Recycler：プラスミドDNA合成の新技術
• ウイルスベクターおよびプラスミドDNA技術市場：製品タイプ別
• ウイルスベクターおよびプラスミドDNA技術市場：用途別
• ウイルスベクターおよびプラスミドDNA技術市場：地域別
• 概要
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• その他の地域
• ウイルスベクターおよびプラスミドDNA技術市場における持続可能性：ESGの観点
• 環境要因
• 社会的要因
• ガバナンス要因
• 大手企業のESGパフォーマンス
• 主要企業のESGパフォーマンス
• Lonza：ESGパフォーマンス
• Thermo Fisher：ESGパフォーマンス
• 総論

第8章 付録

List of Tables

• Table 1 : Global Market for Gene Editing Therapeutics, Through 2029
• Table 2 : Comparison of Genome-Editing Tools
• Table 3 : U.S. Adults Age 50 Years and Older with Multiple Chronic Conditions, 2020-2050
• Table 4 : Global Cases and Deaths Due to Various Cancers, 2022
• Table 5 : Comparison of Cas9-derived Proteins with Regular SpCas9
• Table 6 : Global Market for Gene Editing Therapeutics, Through 2029
• Table 7 : Global Market for Gene Editing Therapeutics, by Region, Through 2029
• Table 8 : ESG Initiatives/Practices by Various Gene Editing Companies, 2023
• Table 9 : ESG Rankings for Companies in the Gene Editing Therapeutics Market, 2023
• Table 10 : Global DNA Sequencing Market, by Region, Through 2029
• Table 11 : DNA Transcription and Translation
• Table 12 : Types of Genetic Variation
• Table 13 : Molecular Diagnostic Technology Platforms
• Table 14 : Main Sequencing Applications
• Table 15 : Genetic Analysis Platform Comparison
• Table 16 : Key Applications in Microbial Sequencing
• Table 17 : Global DNA Sequencing Market, by Technology, Through 2029
• Table 18 : Different Generations of NGS Platforms
• Table 19 : Global DNA Sequencing Market, by Region, Through 2029
• Table 20 : Environmental Performance Initiatives in the DNA Sequencing Market
• Table 21 : Social Performance Initiatives in the DNA Sequencing Market
• Table 22 : Governance Performance Initiatives in the DNA Sequencing Market
• Table 23 : ESG Rankings for Key Players in DNA Sequencing Market, 2024*
• Table 24 : Global Market for Clinical Applications of Next-Generation Sequencing, by Disease Class, Through 2028
• Table 25 : Forces Influencing Growth in the Clinical NGS Market
• Table 26 : Key Trends in the Clinical NGS Testing Market
• Table 27 : Future Challenges in Implementing Clinical NGS
• Table 28 : Clinical NGS Research and Development Initiatives and Programs
• Table 29 : Global Market for Clinical NGS, by Disease Category, Through 2028
• Table 30 : Global Market for Clinical NGS, by Region, Through 2028
• Table 31 : Key Focus Areas in ESG Metrics
• Table 32 : ESG Rankings for Major Companies in the NGS Arena
• Table 33 : Illumina 2030 ESG Targets
• Table 34 : Global Market for RNA Sequencing, by Product, Through 2029
• Table 35 : Global Market for RNA Sequencing, by Technology, Through 2029
• Table 36 : Types of RNAs in Cells
• Table 37 : Comparison of Transcriptomics Methods
• Table 38 : Functional Elements in Sequencing Adapters
• Table 39 : Overview of Illumina's Sequencing Instruments
• Table 40 : Cloud Computing Providers for Genomics/RNA-Seq
• Table 41 : Global Market for RNA Sequencing, by Region, Through 2029
• Table 42 : Research Initiatives Focused on Personalized Medicine in Europe
• Table 43 : Key Focus Areas in ESG Metrics
• Table 44 : Environmental Performance Initiatives in the RNA Sequencing Market
• Table 45 : Social Performance Initiatives in the RNA Sequencing Market
• Table 46 : Governance Performance Initiatives in the RNA Sequencing Market
• Table 47 : ESG Rankings for Key Players in RNA Sequencing Market, 2024*
• Table 48 : Global Market for RNAi Technology, by Technology Type, Through 2029
• Table 49 : Cost Comparison of siRNA-approved Drugs and Alternative Therapies
• Table 50 : Global Market for RNAi Technology, by Technology Type, Through 2029
• Table 51 : RNAi Approved Drugs List
• Table 52 : miRNA-based Diagnostic Tools Available in Clinical Settings
• Table 53 : Global Market for RNAi Technology, by Region, Through 2029
• Table 54 : Key Focus Areas in ESG Metrices
• Table 55 : Environmental Initiatives, by Various RNAi Technology Companies
• Table 56 : ESG Rankings for Companies in the RNAi Technology Market, 2023
• Table 57 : Alnylam's ESG initiatives
• Table 58 : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
• Table 59 : Global Incidence of All Cancers, by WHO Region, 2022-2050
• Table 60 : Global Market for Viral Vector and Plasmid DNA Technologies, Through 2028
• Table 61 : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, Through 2028
• Table 62 : Global Market for Viral Vector and Plasmid DNA Technologies, by Application, Through 2028
• Table 63 : Global Market for Viral Vector and Plasmid DNA Technologies, by Region, Through 2028
• Table 64 : ESG Rankings of Major Companies, 2024*
• Table 65 : Lonza: ESG Performance
• Table 66 : Thermo Fisher: ESG Performance

List of Figures

• Figure 1 : Global Market for Gene Editing Therapeutics, 2021-2029
• Figure 2 : Emerging Technologies in the Genome-Editing Therapeutics Market
• Figure 3 : Global DNA Sequencing Market Shares, by Region, 2023
• Figure 4 : Global Market Shares of DNA Sequencing, by Technology, 2023
• Figure 5 : Global DNA Sequencing Market Shares, by Region, 2023
• Figure 6 : Global Market for Clinical Applications of Next-Generation Sequencing, by Disease Class, 2020-2028
• Figure 7 : Key Sustainable Practices Being Implemented in Research Laboratories
• Figure 8 : Global Market for RNA Sequencing, by Product, 2021-2029
• Figure 9 : Global Market for RNA Sequencing, by Technology, 2021-2029
• Figure 10 : RNA-Seq Experiments for Transcriptomics
• Figure 11 : RNA-Seq Experimental Workflow
• Figure 12 : Growth Strategy Recommendations: RNA Sequencing Market
• Figure 13 : Average Cost Per Genome: Y-o-Y Trend, 2011-2022
• Figure 14 : Global Market Shares of RNA Sequencing, by Product, 2024
• Figure 15 : Global Market Shares of RNA Sequencing, by Region, 2024
• Figure 16 : Growth Drivers in Asia-Pacific RNA Sequencing Market
• Figure 17 : Global Market for RNAi Technology, by Technology Type, 2021-2029
• Figure 18 : Global Market Shares of RNAi Technology, by Technology Type, 2023
• Figure 19 : Global Market for RNAi Technology, by Region, 2021-2029
• Figure 20 : Global Market Shares of RNAi Technology, by Region, 2023
• Figure 21 : Global Market for Viral Vector and Plasmid DNA Technologies, by Product Type, 2020-2028
• Figure 22 : Global Market Shares of Viral Vector and Plasmid DNA Technologies, by Product Type, 2022

The global market for DNA sequencing is expected to grow from $14.8 billion in 2024 and is projected to reach $34.8 billion by the end of 2029, at a compound annual growth rate (CAGR) of 18.6% during the forecast period of 2024 to 2029.

The global market for clinical applications of next-generation sequencing is estimated to increase from $21.9 billion in 2023 to reach $52.9 billion by 2028, at a CAGR of 19.3% from 2023 through 2028.

The global market for RNA sequencing is expected to grow from $4.3 billion in 2024 and is projected to reach $10.3 billion by the end of 2029, at a CAGR of 19.1% during the forecast period of 2024 to 2029.

Research Review Scope

DNA and RNA synthesis artificially manufactures deoxyribose nucleic acid (DNA) and ribonucleic acid (RNA). Developing synthetic techniques to construct DNA and RNA has improved the ability to understand and engineer biology. Different types of synthesized DNA, such as oligonucleotides, genes, and DNA and RNA fragments, are available and can be utilized per the customer's needs. Synthetic DNA and RNA are used to develop new drugs and vaccines, gene therapies for genetic disorders, and the development of molecular diagnostic tools, including polymerase chain reaction (PCR) assays and nucleic-acid-based sensors, to detect pathogens and diseases.

DNA and RNA synthesis technology is vital in scientific fields such as synthetic biology, molecular genetics, and bioengineering, creating custom DNA and RNA sequences for various research, diagnostic, and therapeutic applications. The rapid expansion of genomics research, advancements in therapeutic DNA and RNA applications, and the growing need for personalized medicine are driving exceptional growth in the DNA & RNA synthesis market. The innovations in CRISPR, gene therapy, and synthetic biology show that the demand for DNA and RNA synthesis has risen sharply, positioning it as a pivotal tool in developing targeted treatments and innovative genetic research solutions.

Research Reviews from BCC Research provide market professionals with concise market coverage within a specific research category. This 2024 Research Review of DNA and RNA synthesis technology provides a sampling of the type of quantitative market information, analysis, and guidance that BCC Research has been developing since its inception in 1971 to help its customers make informed business decisions. This Research Review includes highlights and excerpts from the following reports published by BCC Research in 2024:

• BIO259A Gene Editing Therapeutics Market
• BIO045J Global DNA Sequencing: Research Applied and Clinical Markets
• BIO126E Next-generation Sequencing: Emerging Clinical Applications and Global Markets
• BIO147B RNA Sequencing: Technologies and Global Markets
• BIO127C RNAi Technologies and Global Markets
• BIO192B Viral Vector and Plasmid DNA: Technologies and Global Markets

After you survey the excerpts in this Research Review, we encourage you to follow up on these topics by checking out the full market research reports associated with each topic. BCC Research looks forward to serving your market intelligence needs in the future.

Table of Contents

Chapter 1 Foreword

• Research Review Scope

Chapter 2 Gene Editing Therapeutics Market (BIO259A)

• Scope of Report of Gene Editing Therapeutics
• Market Outlook of Gene Editing Therapeutics
• Market Summary
• Market Overview of Gene Editing Therapeutics
• Genome-Editing Tool Types
• Meganucleases
• Zinc Finger Nucleases
• Transcription Activator-like Effector Nucleases
• Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-Associated Protein 9
• Gene editing Therapeutics
• Market Dynamics of Gene Editing Therapeutics
• Market Driver
• Market Challenges
• Emerging Technologies and Opportunities of Gene Editing Therapeutics
• Base Editing
• Prime Editing
• Cas-Clover and Cas-FOKl
• CRISPR Interference and CRISPR Activation
• RNA Editing
• Artificial Intelligence in Genome Editing
• Market Analysis of Gene Editing Therapeutics
• Overview
• Casgevy
• Market of Gene Editing Therapeutics by Region
• North America
• Europe
• Emerging Markets
• ESG Performance in Gene Editing Therapeutics Market
• ESG Practices in the Gene Editing Companies
• Concluding Remarks from BCC Research

Chapter 3 Global DNA Sequencing: Research, Applied and Clinical Markets (BIO045J)

• Scope of Report of DNA Sequencing: Research, Applied and Clinical Markets
• Market Outlook of DNA Sequencing: Research, Applied and Clinical Markets
• Market Summary of DNA Sequencing: Research, Applied and Clinical Markets
• Market Overview of DNA Sequencing: Research, Applied and Clinical Markets
• Importance of DNA
• Genetic Variation and Analysis
• NGS (Second-generation Sequencing)
• TGS (Long-read Sequencing)
• Research and Applied Applications
• R&D Applications
• Applied Applications
• Direct to Consumer
• Biopharma
• Agriculture
• Forensics
• Microbiome
• Synthetic Biology
• Market Dynamics of DNA Sequencing: Research, Applied and Clinical Markets
• Market Driver
• Market Restraint
• Emerging Technologies of DNA Sequencing: Research, Applied and Clinical Markets
• Long-read Sequencing Technologies
• SMRT Sequencing
• Nanopore Sequencing
• Spatial Genomics and Transcriptomics
• Single-cell DNA Sequencing
• Ultra-low Input Sequencing
• CRISPR-Cas9 and Genome-editing Integration with Sequencing Technologies
• AI and Machine Learning in DNA Sequencing
• Market Breakdown of DNA Sequencing: Research, Applied and Clinical Markets by Technology
• Overview
• NGS
• TGS
• Sanger Sequencing
• Pyrosequencing
• Market Breakdown of DNA Sequencing: Research, Applied and Clinical Markets by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World
• ESG Performance in DNA Sequencing Industry
• Environmental Performance
• Social Performance
• Governance Performance
• ESG Risk Ratings in the DNA Sequencing Industry
• Concluding Remarks from BCC Research

Chapter 4 Next-generation Sequencing: Emerging Clinical Applications and Global Markets (BIO126E)

• Scope of Report of Next-generation Sequencing
• Market Outlook of Next-generation Sequencing
• Market Summary of Next-generation Sequencing
• Market Overview of Next-generation Sequencing
• Liquid and Tissue Biopsy
• Growth Drivers of Clinical NGS
• Key Trends
• Market Dynamics of Next-generation Sequencing
• Market Driver
• Market Restraint
• Emerging Technologies of Next-generation Sequencing
• R&D Initiatives and Programs
• 1+ Million Genomes
• Access to Treatment and Testing (ACTT)
• Access to Comprehensive Genomic Profiling Coalition (ACGP)
• Africa Pathogen Genomics Initiative
• Blood Profiling Atlas
• Cancer-ID
• Cancer Moon Shots Program
• China Precision Medicine Initiative
• ClinGen
• CTC Trap Consortium
• diaRNAgnosis Project
• Early Cancer Detection Consortium
• EpiFemCare
• France Genomic Medicine Plan
• Friends of Cancer Research Project
• Genomic Medicine Sweden
• HCA-Organoid
• Human Cell Atlas
• Human Immunomics Initiative
• Immunomonitor Consortium
• Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy Program
• Intervene
• Liquid Biopsies and Imaging for Improved Cancer Care
• Liquid Biopsy-Based Malignant Tumor Early Screening Technology Research and Development Project
• Liver Cancer Early Screening Comprehensive Prevention and Control Project
• Lung Cancer Genomic Screening Project for Individualized Medicine in Asia
• Million Veteran Program
• Medical Genome Initiative
• MedSeq
• Market Breakdown of Next-generation Sequencing by Disease Category
• Overview
• Market Breakdown of Next-generation Sequencing by Region
• North America
• Europe
• Asia-Pacific
• ESG Performance in Next-generation Sequencing Industry
• Case Study
• BCC Research Viewpoint

Chapter 5 RNA Sequencing: Technologies and Global Markets (BIO147B)

• Scope of Report of RNA Sequencing
• Market Outlook of RNA Sequencing
• Market Summary of RNA Sequencing
• Market Overview of RNA Sequencing
• Technology Background
• Transcriptomics Technologies
• RNA Sequencing for Transcriptomics
• RNA-Seq Experimental Workflow
• Regulatory Landscape of RNA Sequencing
• Growth Strategy Recommendations
• Market Dynamics of RNA Sequencing
• Market Drivers
• Market Restraints
• Market Opportunity
• Emerging Technologies and Developments of RNA Sequencing Market
• Single-Cell RNA Sequencing
• Other Emerging Single-Cell Technologies
• Market Breakdown of RNA Sequencing by Product
• Instruments
• Tools and Reagents
• Software and Services
• Market Breakdown of RNA Sequencing by Region
• Overview
• North America
• Europe
• Asia-Pacific
• Rest of the World
• Sustainability in RNA Sequencing Market: ESG Perspective
• ESG Practices in the RNA Sequencing Industry
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC Research

Chapter 6 RNAi Technologies and Global Markets ( BIO127C)

• Scope of Report of RNAi Technologies
• Market Snapshot of RNAi Technologies
• Market Summary of RNAi Technologies
• Market Overview of RNAi Technologies
• RNA Interference Overview
• RNA Interference: Mechanism of Action
• Initiation Phase
• Effector Phase
• Small Interfering RNAs (siRNAs)
• MicroRNAs (miRNAs)
• Small Hairpin RNAs (shRNAs)
• Market Dynamics of RNAi Technologies
• Market Drivers
• Market Challenges
• Emerging Technologies and Opportunities of RNAi Technologies
• Therapeutics
• Diagnostics
• Circulating miRNA Diagnostics for Non-invasive Health Monitoring
• Agriculture
• Market for RNAi Technology by Technology
• Therapeutics
• Diagnostics
• Reagents and Tools
• Agriculture
• Market for RNAi Technology by Region
• Overview
• North America
• Europe
• Emerging Markets
• Sustainability in RNAi Technology Industry: An ESG Perspective
• Environmental Initiatives
• Social Initiatives
• Governance Initiatives
• Case Study
• Concluding Remarks from BCC

Chapter 7 Viral Vector and Plasmid DNA: Technologies and Global Markets (BIO192B)

• Scope of Report of Viral Vector and Plasmid DNA
• Market Outlook of Viral Vector and Plasmid DNA
• Market Summary of Viral Vector and Plasmid DNA
• Market Overview of Viral Vector and Plasmid DNA
• Cell and Gene Therapy
• Market Dynamics of Viral Vector and Plasmid DNA
• Market Driver
• Market Challenges
• Emerging Technologies and Opportunities of Viral Vector and Plasmid DNA
• AI in Viral Vector Production
• Doggybone DNA
• FRAGment Recycler: A New Technology for Plasmid DNA Synthesis
• Market for Viral Vector and Plasmid DNA Technologies by Product Type
• Market for Viral Vector and Plasmid DNA Technologies by Application
• Market for Viral Vector and Plasmid DNA Technologies by Region
• Overview
• North America
• Europe
• Asia-Pacific
• Latin America
• Rest of the World
• Sustainability in the Market for Viral Vector and Plasmid DNA Technologies: An ESG Perspective
• Environmental Factors
• Social Factors
• Governance Factors
• ESG Performance Among Major Companies
• ESG Performance of Select Companies
• Lonza: ESG Performance
• Thermo Fisher: ESG Performance
• Conclusion

Chapter 8 Appendix

• Methodology
• Analyst's Credentials